These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24900337)

  • 1. Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.
    Chegaev K; Riganti C; Lazzarato L; Rolando B; Guglielmo S; Campia I; Fruttero R; Bosia A; Gasco A
    ACS Med Chem Lett; 2011 Jul; 2(7):494-7. PubMed ID: 24900337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.
    Riganti C; Miraglia E; Viarisio D; Costamagna C; Pescarmona G; Ghigo D; Bosia A
    Cancer Res; 2005 Jan; 65(2):516-25. PubMed ID: 15695394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins.
    Gazzano E; Chegaev K; Rolando B; Blangetti M; Annaratone L; Ghigo D; Fruttero R; Riganti C
    Bioorg Med Chem; 2016 Mar; 24(5):967-75. PubMed ID: 26822567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.
    Doublier S; Riganti C; Voena C; Costamagna C; Aldieri E; Pescarmona G; Ghigo D; Bosia A
    Mol Cancer Res; 2008 Oct; 6(10):1607-20. PubMed ID: 18922976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.
    De Boo S; Kopecka J; Brusa D; Gazzano E; Matera L; Ghigo D; Bosia A; Riganti C
    Mol Cancer; 2009 Nov; 8():108. PubMed ID: 19925669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.
    Kopecka J; Campia I; Brusa D; Doublier S; Matera L; Ghigo D; Bosia A; Riganti C
    J Cell Mol Med; 2011 Jul; 15(7):1492-504. PubMed ID: 20716130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells.
    Ren Z; Gu X; Lu B; Chen Y; Chen G; Feng J; Lin J; Zhang Y; Peng H
    J Cell Mol Med; 2016 Jun; 20(6):1095-105. PubMed ID: 26864945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.
    Riganti C; Doublier S; Costamagna C; Aldieri E; Pescarmona G; Ghigo D; Bosia A
    Mol Pharmacol; 2008 Aug; 74(2):476-84. PubMed ID: 18463201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance.
    Riganti C; Rolando B; Kopecka J; Campia I; Chegaev K; Lazzarato L; Federico A; Fruttero R; Ghigo D
    Mol Pharm; 2013 Jan; 10(1):161-74. PubMed ID: 23186264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
    Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
    Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin.
    Miraglia E; Viarisio D; Riganti C; Costamagna C; Ghigo D; Bosia A
    Int J Cancer; 2005 Jul; 115(6):924-9. PubMed ID: 15729714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells.
    Rajendra Prasad VV; Deepak Reddy G; Kathmann I; Amareswararao M; Peters GJ
    Bioorg Chem; 2016 Feb; 64():51-8. PubMed ID: 26657603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells.
    Pannocchia A; Revelli S; Tamponi G; Giorgianni A; Todde R; Bosia A; Ghigo D
    Cell Biochem Funct; 1996 Mar; 14(1):11-8. PubMed ID: 8907249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of furoxan-based nitric oxide-releasing derivatives of tetrahydroisoquinoline as anticancer and multidrug resistance reversal agents.
    Zou ZH; Lan XB; Qian H; Huang WL; Li YM
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5934-8. PubMed ID: 21843940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.
    Kopecka J; Campia I; Olivero P; Pescarmona G; Ghigo D; Bosia A; Riganti C
    J Control Release; 2011 Jan; 149(2):196-205. PubMed ID: 20946921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.
    Bigagli E; Luceri C; De Angioletti M; Chegaev K; D'Ambrosio M; Riganti C; Gazzano E; Saponara S; Longini M; Luceri F; Cinci L
    Invest New Drugs; 2018 Dec; 36(6):985-998. PubMed ID: 29607467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts.
    Evig CB; Kelley EE; Weydert CJ; Chu Y; Buettner GR; Burns CP
    Nitric Oxide; 2004 May; 10(3):119-29. PubMed ID: 15158691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
    Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes.
    Oudard S; Thierry A; Jorgensen TJ; Rahman A
    Cancer Chemother Pharmacol; 1991; 28(4):259-65. PubMed ID: 1678995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.